Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... the weeks since DEMO 2007, I've had the chance to ... site, Jaman.com . Launched at the conference, Jaman.com offers ... or buy at prices that average about $6 per film. ... core of the Jaman.com experience is the downloadable player, a ...
... Wis. - Looking to raise more venture capital for ... 30 firms presenting at the annual InvestMidwest venture capital ... which also presented at the 2006 forum, would like to ... Phase I clinical trials that are set to begin in ...
... a recent column for the Wisconsin Technology Network , Gov. ... Wisconsin System fueling our state's economy. The governor missed the mark. ... the best in the country. In order to remain on top, however, ... done little of since it was created in 1971. The UW System ...
Cached Biology Technology:We're "Jaman": Purpose-driven browsers drive next wave of Web applications 2We're "Jaman": Purpose-driven browsers drive next wave of Web applications 3ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3UW System must remove barriers to innovation 2UW System must remove barriers to innovation 3UW System must remove barriers to innovation 4
(Date:10/15/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... mobile commerce market releases photos and video of the recent opening ... 13 th . Gino Pereira , CEO ... investor Mr. Chad A. Verdi rang the bell.  ... investors and employees "for their work and dedication in bringing the ...
(Date:10/15/2014)... Lithuania , Oct. 15, 2014   ... technologies, today announced the availability of the ... VeriLook Surveillance 3.0 provides real-time biometric face identification ... high-resolution digital surveillance cameras. The new version not ... and differentiates people from objects while they are ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... - Eurofins MWG Operon, an expert in next generation sequencing ... libraries for sequencing with Roche GS FLX or Illumina HiSeq ... long paired end (LPE) libraries with different jumping distances (3 ... After sequencing, the resulting reads are assembled into large contigs ...
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... found attached to the foot of an ancient Egyptian mummy ... parts, says the scientist who tested replicas on volunteers. ... a three-part wood and leather artefact housed in the Egyptian ... Chester artificial toe on display in the British Museum, not ...
Cached Biology News:Mummies' false toes helped ancient Egyptians walk 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An N-nitroso-containing ... nitric oxide donor in pancreatic islets. ... Causes DNA alkylation and DNA strand ... ≥95% by HPLC. Soluble in H ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: